Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, ...

Novo Nordisk's Wegovy will soon come in a pill form that's as effective as with a needle. A new study shows Wegovy taken once ...

The Novo Nordisk RTO mandate could be a strategy to encourage attrition, but if community-building is the goal, additional ...

Novo Nordisk's shares rose by 5.4% on Thursday as investors turned more positive about the Danish drugmaker's prospects ...

“Currently, less than 2% of individuals with obesity in the U.S. receive obesity medication and Wegovy in a pill may also ...

Wegovy has been a hugely popular treatment since the Food and Drug Administration (FDA) approved it for weight loss in ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Novo Nordisk A/S is a strong buy for 2024, with cutting-edge drug approvals, cost savings, and robust long-term growth potential. Click for my NVO stock update.

The changes come five weeks into the tenure of new CEO Maziar Mike Doustdar. Doustdar was tapped to replace Novo's previous ...

The struggling Danish company says it looks to reorganize, with the impact on North Carolina workers still unclear.

Novo Nordisk A/S (NYSE:NVO) is one of the best beginner stocks to buy, according to analysts. On September 17, Berenberg upgraded Novo Nordisk from ‘Hold’ to ‘Buy’, and revised its price target to ...